Your Messages Inbox
Your Article Summary
See Latest ArticlesBristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Review Period for Acquisition of Medarex, Inc.
Bristol Myers-Squibb Company, 08/13/09
Bristol–Myers Squibb Company announced that the Hart–Scott–Rodino review period for its tender offer for Medarex, Inc. has expired. Bristol–Myers Squibb initiated on July 2009, through its wholly–owned subsidiary Puma Acquisition Corporation, a cash tender offer to purchase all outstanding shares of common stock of Medarex for $16 per share.
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Mandatory Disclosure of Pharmaceutical Industry-Funded Events for Health Professionals
PLoS Medicine, 12/02/09
FDA drug approval intervals from 1997 to 2006: analysis and comparison during information technology implementation
International Journal of Electronic Healthcare , 12/01/09
Article Search
Sponsor